Anthropic Partners With Six Drug Developers to Speed Medicine Discovery, Launches In-House Programs
AnthropicAI · x · 2026-10-28
Anthropic's life sciences team reports early results from deep research partnerships with six medicine developers — BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group — and has begun in-house drug discovery efforts, including programs for rare childhood forms of muscular dystrophy.
- Strategy: the bottlenecks in drug development are distributed across the whole pipeline — target identification, molecule design, manufacturing optimization, regulatory filings, clinical trial design — so Anthropic embeds in real drug programs across many disease areas and stages rather than focusing on a single problem.
- The team plans to scale this work substantially and acknowledges Claude needs further improvement to realize AI's potential in medicine.
More from AGI Musings
- Report: OpenAI's unreleased internal model Astra billed as start of the AGI era, internal AGI possible by year-end — haider1 · 2026-10-28
- Researcher: huge theorem verifying bug-free shows math literature is pristine training data — rbhar90 · 2026-10-28
- Reddit essay: AI is shattering the last human illusion that intelligence is ours alone — Hope999991 · 2026-10-28
- Bindu Reddy: a dozen AI models will handle all mundane white-collar work in six months — bindureddy · 2026-10-28
- Freeman Dyson's JASON anecdote: elite minds failed badly in wet labs — a lesson for AI — rbhar90 · 2026-10-28
- AI is the ultimate aggregator: information plus actions at universal scale — signulll · 2026-10-28